Accumulating literature shows that treatment with a BRAF inhibitor such as PLX4720 enriches a slow-cycling cancer stem cell-like (CSC) subpopulation of melanoma cells that is characterized by stem cell markers such as Lysine-Specific Demethylase 5B (JARID1B) and spheroid formation [44,45]. The gene discussed is BRAF; the disease is cancer.